Malaria Vac`cines Market Share, Demand, Industry Trends, Growth Opportunities and Revenue Outlook

Comments · 128 Views

Malaria Vaccines Market Share, Demand, Industry Trends, Growth Opportunities and Revenue Outlook

Malaria's prevalence in tropical nations has been a source of concern for the entire world, causing millions of fatalities during the last ten years. Vaccine development is an essential component of effective interventional control. In recent years, there has been a lot of study into new vaccine options. A diversified pipeline has been studied based on ongoing malaria life-cycle research. Understanding the biology of the deadly human malaria parasites Plasmodium falciparum and Plasmodium vivax is critical for expanding opportunities in the malaria vaccine industry. New options in the malaria vaccine business have opened up thanks to generations of pre-erythrocytic vaccinations. This has sparked a flurry of interest from biotech firms. RTS, S/AS01 (RTS,S) is the most thoroughly investigated vaccine option for P. falciparum malaria prophylaxis.

Data Bridge Market Research analyses that the malaria vaccines market was valued at USD 1,852.38 million in 2021 and is expected to reach USD 18,913.86 million by 2029, registering a CAGR of 33.70% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

View Detailed Report@  https://www.databridgemarketresearch.com/reports/global-malaria-vaccines-market  

 Market Definition

Malaria vaccines are treatments that protect against malaria, a mosquito-borne infectious disease. Malaria, commonly known as plasmodium infection, is spread via the bite of infected female anopheles mosquitos. Chills, fever, and sweating are symptoms of this long-term sickness. These vaccines can be given in various ways, including intramuscular, subcutaneous, and intradermal injections. The World Health Organization (WHO) recommends that these vaccinations be used in places where there is a high burden of disease and malaria transmission.

Malaria Vaccines Market Dynamics

Drivers

  • Rise in the prevalence of malaria in low-income countries

The rise in prevalence of malaria in low-income countries is anticipated to flourish the market's growth rate. Malaria is a life-threatening infectious disease spread by female Anopheles mosquitoes and caused by the Plasmodium parasite. The malaria epidemic is spreading, and climate change is making it easier for mosquito vectors to thrive. According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America. In addition, malaria is most common in Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of malaria vaccines market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, increases in number of patient awareness level as well as government initiatives and growing application of malaria vaccines in various therapeutic conditions will expand the malaria vaccines market. Additionally, the implementation of favourable government policies to promote global health and medical science advancement are estimated to enhance the market’s growth rate.

Recent Development

  • In October 2021, GlaxoSmithKline (GSK) plc welcomes and applauds the World Health Organization's (WHO) proposal to expand the use of GSK's RTS,S malaria vaccine in children living in Sub-Saharan Africa and other locations with moderate to high transmission, as defined by WHO. RTS,S is the first and only malaria vaccine to be shown to reduce malaria in children in key long-term clinical trials dramatically. The vaccine is the result of more than 30 years of work by GSK, PATH, and other collaborators.

 

Some of the major players operating in the malaria vaccines market are:

  • Actiza Pharmaceutical Private Limited (India)
  • AdvaCare Pharma (U.S.)
  • Ipca Laboratories Ltd. (India)
  • Bliss GVS Pharma Ltd. (India)
  • GeoVax (U.S.)
  • Sumaya Biotech (Germany)
  • VLP Therapeutics (U.S.)
  • OSIVAX (France)
  • AJANTA PHARMA (India)
  • Strides Pharma Science Limited (India)
  • Mylan N.V. (U.S.)
  • Zydus Cadila (India)
  • Cipla Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Sanofi (France)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Taj Pharmaceuticals Limited. (India)
  • Lupin (India)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

Read more